Patents Assigned to ImmunoMolecular Therapeutics, Inc.
  • Compounds and methods for treating autoimmune disorders by targeting HLA-DQ2
    Patent number: 11945790
    Abstract: Compounds and compositions useful in methods of treating, ameliorating, or inhibiting the development of an autoimmune disease by modulating the T cell response to antigenic peptide or fragments of antigenic peptides presented by the major histocompatibility (MHC) class II molecule, DQ2.
    Type: Grant
    Filed: December 21, 2021
    Date of Patent: April 2, 2024
    Assignee: ImmunoMolecular Therapeutics, Inc.
    Inventors: Robert B. Perni, Ryan Schutte, James M. Siedlecki
  • Compounds and methods for treating autoimmune disorders by targeting HLA-DQ2
    Patent number: 11939300
    Abstract: Compounds and compositions useful in methods of treating, ameliorating, or inhibiting the development of an autoimmune disease by modulating the T cell response to antigenic peptide or fragments of antigenic peptides presented by the major histocompatibility (MHC) class II molecule, DQ2.
    Type: Grant
    Filed: August 20, 2021
    Date of Patent: March 26, 2024
    Assignee: ImmunoMolecular Therapeutics, Inc.
    Inventors: Robert B. Perni, Ryan Schutte, James M. Siedlecki, Asha Ghevde
  • Methods for producing D-?-methyldopa
    Patent number: 11702383
    Abstract: The present invention provides methods of synthesizing D-?-methyldopa and L-?-methyldopa.
    Type: Grant
    Filed: December 21, 2021
    Date of Patent: July 18, 2023
    Assignee: ImmunoMolecular Therapeutics, Inc.
    Inventors: Xing Fu, Rajesh Shukla
  • Compounds and methods for treating autoimmunity
    Patent number: 11052060
    Abstract: Compounds and compositions useful in methods of treating, ameliorating, or inhibiting the development of autoimmune diseases or Celiac disease by modulating the binding of DQ8 MHC class II molecules to antigenic peptides or fragments of antigenic peptides.
    Type: Grant
    Filed: March 19, 2019
    Date of Patent: July 6, 2021
    Assignees: The Regents of the University of Colorado, a body corporate, ImmunoMolecular Therapeutics, Inc.
    Inventors: Steve Orndorff, Aaron Michels
  • Administration of oral methyldopa
    Patent number: 11013707
    Abstract: Methods of administering methyldopa to a subject in a fasting state to increase bioavailability of the methyldopa.
    Type: Grant
    Filed: March 23, 2018
    Date of Patent: May 25, 2021
    Assignees: The Regents of the University of Colorado, a body corporate, ImmunoMolecular Therapeutics, Inc.
    Inventors: Steve Orndorff, Aaron Michels